Eli Lilly and Company $LLY Shares Acquired by RWA Wealth Partners LLC

RWA Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,481 shares of the company’s stock after buying an additional 948 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of RWA Wealth Partners LLC’s holdings, making the stock its 27th biggest position. RWA Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $49,962,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Laurel Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank bought a new position in Eli Lilly and Company during the 2nd quarter worth $8,827,714,000. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Franklin Resources Inc. increased its position in Eli Lilly and Company by 13.4% in the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the period. Finally, Canada Pension Plan Investment Board lifted its stake in Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after buying an additional 536,679 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.5%

Shares of NYSE:LLY opened at $1,042.68 on Wednesday. The company has a 50 day moving average of $1,054.49 and a 200-day moving average of $923.72. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm has a market cap of $983.62 billion, a P/E ratio of 45.43, a P/E/G ratio of 1.23 and a beta of 0.39. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 30.15%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Morgan Stanley upped their price target on shares of Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. CICC Research upped their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Leerink Partners lifted their price target on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,229.33.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo’s next‑gen CagriSema failed to match Lilly’s tirzepatide, reinforcing Lilly’s clinical leadership and market share prospects. Novo’s stumbles burnish Lilly’s widening lead
• Positive Sentiment: Product/label expansion: FDA cleared a multi‑dose KwikPen for Zepbound (tirzepatide), sold at the same self‑pay price — a convenience/retention strategy that supports prescriptions and stickiness. Zepbound KwikPen press release
• Positive Sentiment: Analyst support: Goldman Sachs and other firms continue to view Lilly as a top obesity/diabetes play, reiterating buy ratings and high price targets, which underpins investor confidence. TipRanks analyst note
• Neutral Sentiment: Retention push: Lilly is promoting the multi‑dose pen as a way to improve patient retention vs. single‑use devices — operationally positive but longer‑term for revenue impact. Invezz: multi-dose pen strategy
• Negative Sentiment: Price‑cut shock: Novo announced U.S. list prices for Ozempic/Wegovy will be halved (~$675/mo) starting 2027 — the prospect of steeper pricing competition prompted a pullback in LLY shares amid fears of margin/volume shifts across the class. Eli Lilly slips on Novo Nordisk price cut plans
• Negative Sentiment: Investor concern: Commentary flagged that aggressive pricing by Novo could change market dynamics and potentially impact Lilly’s revenue trajectory, creating near‑term uncertainty despite Lilly’s strong positioning. Fool: Why Eli Lilly Stock Slumped

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.